Menu Close

RNA medicines

Chronic liver disease is the
only top ten global killer
that’s on the rise
Ochre Bio - RNA medicines for chronic diseases


More donor livers are being discarded

Many donor livers are too unhealthy to be transplanted and go to waste, despite one in six patients dying while waiting for a new liver. The main reason for discarding a donor liver is that it contains too much fat.

By 2030, it’s estimated that over half of donor livers will be discarded.

Orman ES et al. (2015) doi: 10.1002/lt.24160

Proportion of discaded donor livers

Cardiometabolic disease is the leading cause of death

Obesity and age are rapidly becoming the main combined reason for liver failure, where a transplant has become the only solution. In fact, obesity and age are the main risk factors behind many chronic diseases that result in four out of ten deaths. This statistic continues to rise, as our population become older and more obese.

Fat in the liver contributes to more deaths than all cancers combined.

  • Ochre Bio’s target diseases
  • Diseases we aren’t targeting

Institute for Health Metrics and Evaluation. Used with permission. All rights reserved

  • Cardiovascular Diseases
  • Cancer
  • Respiratory Diseases
  • Diabetes
  • Lower Respiratory Infections
  • Dementia
  • Neonatal Deaths
  • Diarrhoeal Diseases
  • Road Injuries
  • Metabolic Liver Diseases
  • Cardiovascular Diseases
  • Cancer
  • Respiratory Diseases
  • Diabetes
  • Lower Respiratory Infections
  • Dementia
  • Neonatal Deaths
  • Diarrhoeal Diseases
  • Road Injuries
  • Metabolic Liver Diseases


Deep Phenotyping

‘Big data’ is delivering on its promise to improve drug development, with machine learning (‘AI’) decoding disease much cheaper, and high-throughput workflows decoding network biology much faster. Ochre Bio’s approach is firmly rooted in such computational and systems-driven learning. However, our goal is also to decode substantially better.

Not just fail fast, but fail less with the correct type of big data with which to train our models. Ochre Bio brings an extra dimension to drug development data, called deep phenotyping. Deep phenotyping combines genetics, advanced tissue imaging, cellular genomics (single-cell and spatial sequencing), and machine learning, to study disease and gene systems at a tissue level.

Ochre Bio - Deep Phenotyping

Our 100% human focus involves the deep phenotyping of human biobanks, deep phenotyping of genetically perturbed human micro-organs (in vitro) models and the deep phenotyping of diseased human organs perfused outside of the body.

This 100% human approach to data provides a distinct advantage when studying complex age-associated and chronic diseases that require more than simple single-target therapies.


Metabolic Stress

Pretreat suboptimal donor livers; treat non-symptomatic cirrhosis.

Prevent recurrence of fatty liver post-transplant; treat morbid obesity.

Buy more time for those with end-stage disease; treat decompensated cirrhosis.

Status: Discovery Lead Dev. Preclinical IND Enabling Clinical
  • Discovery
  • Lead Dev.
  • Preclinical
  • IND Enabling
  • Clinical
Transplant (donor) Ochre Bio - Regenerative


  • Our Core Team
  • Our Wider Team

Ochre Bio was founded out of 15 years leading liver genomics research and experience in bringing advanced therapies to market. We really love what we do, and are always on the lookout for new team members who aren't afraid to think out of the box.

We have compiled a highly specialised group of advisors, consultants, and investors to help craft our strategy. Our combination of US and European investors, with traditional life sciences as well as genomics and technology expertise, underscores the type of company we are building.

Paul Foster Paul Foster
Paul Foster
Head of Finance, Acting CFO - No Lab
Phoebe Oldach Phoebe Oldach
Phoebe Oldach
Target Validation - Dry Lab
Kenny Moore Kenny Moore
Kenny Moore
Head of Oxford Labs, UK - Wet Lab
Tess Lu Tess Lu
Tess Lu
Head of Taipei Labs, Taiwan - Wet Lab
Allan Weber Allan Weber
Allan Weber
Head of Global Transplant Programs - No Lab
Jack O’ Meara Jack O’ Meara
Jack O’ Meara
Co-Founder, CEO - No Lab
Fabio Sanna Fabio Sanna
Fabio Sanna
Principal Scientist - Dry and Wet Lab
Jörn Schmiedel Jörn Schmiedel
Jörn Schmiedel
Principal Scientist - Dry and Wet Lab
Vassilis Ragoussis Vassilis Ragoussis
Vassilis Ragoussis
Commercial Operations - No Lab
Quin Wills Quin Wills
Quin Wills
Co-Founder, CSO - Dry and Wet
Raphael Castellan Raphael Castellan
Raphael Castellan
Target Validation - Dry Lab
Ana Cuervo Ana Cuervo
Ana Cuervo
Target Validation - Wet Lab
Valentina Greto Valentina Greto
Valentina Greto
Target Validation - Wet Lab
Frances Willenbrock Frances Willenbrock
Frances Willenbrock
Scientific Operations Manager - Wet Lab
Cheng-Yang Yang Cheng-Yang Yang
Cheng-Yang Yang
Principal Scientist - Wet Lab
Faye Chang Faye Chang
Faye Chang
Target Discovery - Wet Lab
Peter Hutt Peter Hutt
Peter Hutt
Regulatory Law
Alex Morgan Alex Morgan
Alex Morgan
Investor (Khosla)
Alex Brunicki Alex Brunicki
Alex Brunicki
Investor (Backed VC)
Jens Eckstein Jens Eckstein
Jens Eckstein
Investor (Apollo Health)
Scott Friedman Scott Friedman
Scott Friedman
Medical Affairs
Garvin Warner Garvin Warner
Garvin Warner
Preclinical Development & Toxicology
Alasdair Thong Alasdair Thong
Alasdair Thong
Investor (Selvedge Venture)
Jack Scannell Jack Scannell
Jack Scannell
Financial Analysis of R&D Translation
Leanne Hodson Leanne Hodson
Leanne Hodson
Liver Biology
Peter Friend Peter Friend
Peter Friend
Surgical Collaborator
Lisa Taylor Ash Lisa Taylor Ash
Lisa Taylor Ash
Legal & IP
Marc Lemaitre Marc Lemaitre
Marc Lemaitre
CMC & Manufacturing
George Savage George Savage
George Savage
Regulatory Strategy
Simon Knight Simon Knight
Simon Knight
Transplant Clinical Development
Eduardo Martins Eduardo Martins
Eduardo Martins
NASH Clinical Development
Alex Shalek Alex Shalek
Alex Shalek
Target Discovery


Ochre News & Updates

Send us a message

deep phenotyping